Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment

Chest

Volumn 127, Issue 2, 2005, Pages 515-521

  Malerba, Mario ^a   Bossoni, Simonetta ^a   Radaeli, Alessandro ^a   Mori, Erica ^a   Bonadonna, Stefania ^a   Giustina, Andrea ^a   Tantucci, Claudio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adult asthmatic patients; Bone metabolism; Growth hormone; Inhaled corticosteroids

Indexed keywords

CORTICOSTEROID; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OSTEOCALCIN; SOMATOMEDIN;

ADULT; ARTICLE; ASTHMA; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LONG TERM CARE; MALE; OSSIFICATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 13644262558     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.2.515     Document Type: Article

References (29)

1. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart Lung and Blood Institute, April 1997; NIH Publication No. 97-405
2. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148:S1-S26
3. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-955
4. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337:8-14
5. Pauwels RA, Lofdhal CG, Laitinen LA, et al. Effect of long term inhaled budesonide in patients with mild COPD who continue smoking: the Euroscope study. N Engl J Med 1999; 340:1948-1953
6. Toogood JH, Hodsrnan AB. Effects of inhaled and oral corticosteroids on bone. Ann Allergy 1991; 67:87-90
7. Geddes DM. Inhaled corticosteroids: benefit and risks. Thorax 1992; 47:404-407
8. Reid IR. Glucocorticoid-induced osteoporosis. J Clin Densitom 1998; 1:65-73
9. Ohlsson C, Bengtsson BA, Isaksson OG, et al. Growth hormone and bone. Endocr Rev 1998; 19:55-79
10. Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 2000; 11:79-85
11. Bonadonna S, Agabiti Rosei E, Giustina A. Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res 2002; 30:174-183
12. Berneis K, Oehri M, Kraenzlin M, et al. Effects of IGF-1 combined with GH on glucocorticoid-induced changes of bone and connective tissue turnover in man. J Endocrinol 1999; 162:259-264
13. Giustina A, Wehrenberg WB, The role of glucocorticoids in the regulation of growth hormone secretion. Trends Endocrinol Metab 1992; 3:306-311
14. Clausen JL, Coates AL, Quanjer PH. Measurement of lung volumes in humans: review and recommendations from an ATS/ERS workshop. Eur Respir J 1997; 10:1205-1206
15. Quanjer PH. Worldng Party on "Standardisation of Lung Function Tests." Bull Eur Physiopathol Respir 1983; 19:7-10
16. Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 2001; 86:5681-5685
17. Ono T, Kanzaki S, Seino Y, et al. Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like grow factors (IGFs), IGF-binding protein 3 and 5, and bone alkaline phosphatase isoenzyme. J Clin Endocrinol Metab 1996; 81:2111-2116
18. Boot AM, Engels MA, Boerma GJ, et al. Changes in mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J Clin Endocrinol Metab 1997; 82:2423-2428
19. Giustina A, Girelli A, Doga M, et al. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. J Clin Endocrinol Metab 1990; 71:580-584
20. Giustina A, Bossoni S, Bodini C, et al. Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosoppressive glucocorticoid therapy. J Endocrinol Metab 1992; 74:1301-1305
21. Giustina A, Bussi AR, Jacobello C, et al. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 1995; 80:122-129
22. Giustina A, Veldhuis J. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19:717-797
23. Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax, 2001; 56:272-278
24. Richy F, Bousquet J, Ehrlich GE, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003; 14:179-190
25. Canalis E, Bilezikian JP, Angeli A, et al. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004; 34:593-598
26. Terzolo M, Bossoni S, Ali A, et al. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J Clin Endocrinol Metab 2000; 85:1310-1315
27. van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001; 16:581-588
28. Harrison TW. Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs. BioDrugs 2001; 15:405-411
29. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 1:22-28